Task: Answer Verification
Input (English): Question: Does addition of zoledronic acid to neoadjuvant chemotherapy enhance tumor response in patients with HER2-negative stage II/III breast cancer : the NEOZOTAC trial ( BOOG 2010-01 )?
Answer: Addition of ZA to neoadjuvant chemotherapy did not improve pathological or clinical response to chemotherapy. Further investigations are warranted in postmenopausal women with BC, since this subgroup might benefit from ZA treatment.
Output (English): no